Pharyngitis Treatment Market Analysis

Route of Administration Segment Analysis

The oral segment is projected to lead the market, registering 68% of the revenue share by 2035. This rise in growth is mainly attributed to its cost-effectiveness, convenience, and widespread trends in prescription. Oral antibiotics for bacterial pharyngitis, such as amoxicillin and azithromycin, are in the first-line treatments, while NSAIDs like ibuprofen are preferred for viral cases.  The parenteral segment is limited in hospital settings to severe infections. Further, the growth in telemedicine is boosting demand for oral drugs, with plenty of prescriptions issued digitally.

Disease Type Segment Analysis

Bacterial pharyngitis drives the pharyngitis treatment market and is expected to have a share of 60% by 2035. This rise is mainly due to the treatment demand, primarily due to Group A Streptococcus infection requiring antibiotics. the rapid diagnostic tests are minimizing the use of antibiotics. By increasing treatment precision and stewardship initiatives, emerging point-of-care diagnostics may help further segment the market. These factors are augmenting the market growth exponentially during the assessed time period and offer lucrative opportunities for the market players.

Drug Class Segment Analysis

The antibiotics segment is set to garner 37% of the share by 2035, owing to the high prevalence of bacterial pharyngitis. Also, beta-lactams are manufactured on a wide level, mainly in the fast-growing markets such as China and India. Also, the rising adoption of rapid antigen tests aids in more precise segregation between viral and bacterial cases of pharyngitis. In the advanced countries with state-of-the-art healthcare infrastructure, antibiotics benefit from the robust coverage of the insurance and favorable reimbursement policies. These factors are further strengthening the position of the segment as a pioneering treatment modality.

Our in-depth analysis of the global market includes the following segments: